These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9289697)

  • 1. [Prediction of pharmacological effect of octreotide in acromegaly by means of 111In-pentetreotide scintigraphy and calculation of a pituitary uptake index].
    Görges R; Cordes U; Engelbach M; Bartelt KM; Haberern G; Hey O; Beyer J; Bockisch A
    Nuklearmedizin; 1997 Jun; 36(4):117-24. PubMed ID: 9289697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients.
    Legovini P; De Menis E; Billeci D; Conti B; Zoli P; Conte N
    J Endocrinol Invest; 1997; 20(7):424-8. PubMed ID: 9309542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
    Plöckinger U; Bäder M; Hopfenmüller W; Saeger W; Quabbe HJ
    Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of efficacy of octreotide therapy in patients with acromegaly.
    Colao A; Ferone D; Lastoria S; Marzullo P; Cerbone G; Di Sarno A; Longobardi S; Merola B; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2356-62. PubMed ID: 8964877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide.
    Broson-Chazot F; Houzard C; Ajzenberg C; Nocaudie M; Duet M; Mundler O; Marchandise X; Epelbaum J; Gomez De Alzaga M; Schäfer J; Meyerhof W; Sassolas G; Warnet A
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):589-98. PubMed ID: 9425399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels.
    Losa M; Magnani P; Mortini P; Persani L; Acerno S; Giugni E; Songini C; Fazio F; Beck-Peccoz P; Giovanelli M
    Eur J Nucl Med; 1997 Jul; 24(7):728-31. PubMed ID: 9211757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
    Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 111In-octreotide scintigraphy in pituitary adenomas.
    Tofani A; Cucchi R; Pompili A; Carapella C; Crecco M; Mottolese M; Maini CL
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):94-7. PubMed ID: 9002760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands.
    van Royen EA; Verhoeff NP; Meylaerts SA; Miedema AR
    J Nucl Med; 1996 Sep; 37(9):1449-51. PubMed ID: 8790190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole body and tomographic scan with 111In-pentetreotide: preliminary data.
    Gregianin M; Macrì C; Bui F; Varotto L; Zucchetta P
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):124-6. PubMed ID: 9002769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin receptor scintigraphy of a patient with a giant invasive prolactinoma.
    Meyer P; Bohnen NI; Barkan AL; Shapiro B
    Nuklearmedizin; 1999; 38(2):66-7. PubMed ID: 10100234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin receptor scintigraphy in patients with pituitary adenoma.
    Rieger A; Rainov NG; Elfrich C; Klaua M; Meyer H; Lautenschläger C; Burkert W; Mende T
    Neurosurg Rev; 1997; 20(1):7-12. PubMed ID: 9085281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
    Colao A; Lastoria S; Ferone D; Varrella P; Marzullo P; Pivonello R; Cerbone G; Acampa W; Salvatore M; Lombardi G
    J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Somatostatin analogs in the clinical management of pituitary neoplasms].
    Colao A; Dorato M; Pulcrano M; Rossi FW; Auriemma RS; Lombardi G; Lastoria S
    Minerva Endocrinol; 2001 Sep; 26(3):181-91. PubMed ID: 11753242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo.
    Duet M; Ajzenberg C; Benelhadj S; Lajeunie E; Lormeau B; Guillausseau PJ; Rohmer V; Vilain D; Mundler O; Warnet A
    J Nucl Med; 1999 Aug; 40(8):1252-6. PubMed ID: 10450674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scintigraphic assessment of pituitary adenomas and several diseases by indium-111-pentetreotide.
    Tumiati MN; Facchi E; Gatti C; Bossi A; Longari V
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):98-100. PubMed ID: 9002761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.